Opinions Dr. Richard Evans
Amgen Inc.AMGNDON'T BUYJan 25, 2017
Stock price when the opinion was issued
As of Jun 04, 2026. Market Open.
You might be interested:
In the healthcare space, biotech offers more promise than pharma.
Gordon Reid
Was upgraded today. A leader and gives you exposure in large-cap biotech.
Joe Terranova
Really likes it. Breaking out to new highs. He'd be a buyer. Next upside resistance is around the $400 level.
He's been talking to their US sales team about biotech and healthcare in general. If they're correct on the broader market call, then biotech should outperform some of the more defensive areas in healthcare into 2027.
They have 15 of their products growing at double-digits last quarter. Their GLP-1 drug is in phase 3 testing, not yet on the market. Stable management. Pays an outsized dividend.
Gordon ReidThey have 15 of their products growing at double-digits last quarter. Their GLP-1 drug is in phase 3 testing, not yet on the market. Stable management. Pays an outsized dividend.
Gordon ReidThey have 15 of their products growing at double-digits last quarter. Their GLP-1 drug is in phase 3 testing, not yet on the market. Stable management. Pays an outsized dividend.
Gordon Reid
Beaten up a bit, as has the whole space by the Trump administration. Chart shows fantastic trend. Came off a bit, but finding its legs at the lower part of the channel. Hint: on a down day, what goes down less than the market is usually (not always) where the action might come from first.
These guys look at the hard diseases with unmet needs. Executes really well. Fantastic pipeline, and that's what the drug companies are all about. The most money is made buy sitting on your hands; once you take your initial position, just sit back, and in 10 years, you'll be a happy investor. Yield is 3.23%.
One of the oldest biotech companies in the world. Very big portfolio of products. Revenue last quarter up 9%, with 15 products that have double-digit revenue growth in that quarter. Over 20% growth in earnings. Trading ~13x PE.
"Sizzle" is with GLP-1 product (injection, but only once per month) in phase 3 testing and likely coming to market in 2027. Potential game-changer. Yield is 3.46%.
Gordon Reid
If you look at their operating economics, they are very much like a large Pharmaceutical company. Relatively slow moving. Their rate of innovation and patent expiration on all products kind of match, so there is not a lot of upside. The growth that has occurred, much of it on a trailing basis, has come from rising prices on their rheumatoid arthritis drug, but will no longer be able to do that. His belief is that prices are coming down.